Oncologic Effect of Oral Fluorouracil in Hormone Receptor-Negative T1a Node-Negative Breast Cancer Patients

Minsung Kim; Seihyun Ahn; Byungho Son; Jongwon Lee; Bumseok Koh; Guiyeon Sohn; Saebyeol Lee; Hee Jeong Kim

doi:https://doi.org/10.14449/jbd.2016.4.2.116

Oncologic Effect of Oral Fluorouracil in Hormone Receptor-Negative T1a Node-Negative Breast Cancer Patients

Recommendations

Search

Type: Academic journal

Author: Minsung Kim (Department of Surgery Asan Medical Center University of Ulsan College of Medicine) Seihyun Ahn (Department of Surgery Asan Medical Center University of Ulsan College of Medicine) Byungho Son (Department of Surgery Asan Medical Center University of Ulsan College of Medicine)

Journal: 한국유방암학회 Journal of Breast Disease Journal of Breast Disease 제4권 제2호 KCI Accredited Journals

Published: 2016.12

Pages: 116 - 121 (6page)

DOI: https://doi.org/10.14449/jbd.2016.4.2.116

Usage

Oncologic Effect of Oral Fluorouracil in Hormone Receptor-Negative T1a Node-Negative Breast Cancer Patients

Abstract· Keywords

Report Errors

Purpose: As 5-fluorouracil (5-FU) has previously exhibited antitumor activity and few adverse effects in the treatment of breast cancer, we aimed to specifically assess the benefits of orally administered 5-FU in hormone receptor-negative small breast cancer. Methods: We retrospectively identified patients with pT1aN0 and hormone receptor-negative breast cancer who underwent surgery between 1993 and 2008 at Asan Medical Center. Patients were divided into two cohorts based on adjuvant doxifluridine (Didox; Shin Poong Pharm. Co., Ltd.) administration, and the disease-free survival (DFS) and cancer-specific survival (CSS) was assessed for each cohort. Results: Both cohorts had similar ages and tumor sizes. The DFS and CSS did not significantly differ between the groups (p=0.399 and p=0.126, respectively). When the cohorts were assessed according to human epidermal growth factor receptor 2 (HER2) status, doxifluridine significantly improved DFS among patients with T1aN0 and HER2-positive breast cancer (p=0.037). Conclusion: Doxifluridine did not yield a significant reduction in DFS events in hormone receptor-negative early breast cancer. However, a clear benefit was observed in hormone receptor-negative, HER2-positive T1aN0 breast cancer patients.

#Breast neoplasms #Doxifluridine #Hormone receptor #Human epidermal growth factor receptor 2 #Small tumor

No content found

References (20)

Add References

Gamucci T / 2013 / Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis / J Cancer Res Clin Oncol 139:853~860

Vacek PM / 2002 / Increased mammography use and its impact on earlier breast cancer detection in Vermont, 1975-1999 / Cancer 94:2160~2168

Luke C / 2004 / Female breast cancers are getting smaller, but socio-demographic differences remain / Aust N Z J Public Health 28:312~316

Benson JR / 2009 / Early breast cancer / Lancet 373:1463~1479

Hanrahan EO / 2007 / Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma / J Clin Oncol 25:4952~4960

Recommendations

It is an article recommended by DBpia according to the article similarity. Check out the related articles!